logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
C

Charles M. Perou

University of North Carolina at Chapel Hill
H指数:193
被引数:25.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers

抗-CSF-1R疗法与免疫化疗联合可协调适应性免疫应答，以消除巨噬细胞富集的三阴性乳腺癌

Nature Communications
IF15.7
2026-01-030
OA
Diego A. Pedroza; Xueying Yuan; Fengshuo Liu; Hilda L. Chan; Christina Zhang; William Bowie; Alex J. Smith; Sebastian J. Calderon; Nadia Lieu; Weiguo Wu; Paul Porter; Poonam Sarkar; Na Zhao; Constanze V. Oehler; Ondrej Peller; M. Waleed Gaber; Qian Zhu; Charles M. Perou; Xiang H-F. Zhang; Jeffrey M. Rosen
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy

HER2DX在HER2阳性早期乳腺癌老年患者中的应用：来自RESPECT试验中曲妥珠单抗±化疗的扩展随访研究

Nature Communications
IF15.7
2025-11-040
OAAI
Kazuki Nozawa; Masataka Sawaki; Yukari Uemura; Michiko Tsuneizumi; Toshimi Takano; Naomi Gondo; Fumikata Hara; Michiko Harao; Tatsuya Toyama; Naruto Taira; Ana Vivancos; Charles M. Perou; Esther Sanfeliu; Fara Brasó-Maristany; Joel S. Parker; Wesley Buckingham; Laia Paré; Guillermo Villacampa; Mercedes Marín-Aguilera; Patricia Villagrasa; Aleix Prat; Hiroji Iwata
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis

HER2DX和早期HER2阳性乳腺癌的生存结局：一项基于个体患者水平的荟萃分析

lancet oncology
IF0
2025-07-140
PRE
Guillermo Villacampa; Tomás Pascual; Paolo Tarantino; Javier Cortés; José Perez-García; Antonio Llombart-Cussac; Pierfranco Conte; Mario Mancino; Valentina Guarneri; Maria Vittoria Dieci; Adrienne G Waks; Francesco Schettini; Fara Brasó-Maristany; Gaia Griguolo; Beatriz Alonso de Castro; Cristina Reboredo; Silvia Antolín; Coralia Bueno-Muiño; Isabel Echavarría; Sara López-Tarruella; Tatiana Massarrah; María del Monte-Millán; Miguel Martín; Wesley Buckingham; Joel S Parker; Ana Vivancos; Kornelia Polyak; Otto Metzger Filho; Antonio C Wolff; Angela DeMichele; Nadine M Tung; Charles M Perou; Laia Paré; Patricia Villagrasa; Aleix Prat; Sara M Tolaney
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers

CALGB 40601 (Alliance) HER2+乳腺癌新辅助试验的蛋白质组学分析揭示了耐药生物标志物

Cell Reports Medicine
IF10.6
2025-06-050
OA
Eric J. Jaehnig; Aranzazu Fernandez-Martinez; Tanmayi D. Vashist; Matthew V. Holt; LaTerrica Williams; Jonathan T. Lei; Chang In Moon; Beom-Jun Kim; Yongchao Dou; Haoquan Zhao; Viktoriya Korchina; Richard A. Gibbs; Donna Marie Muzny; Harshavardhan Doddapaneni; Charles M. Perou; Lisa A. Carey; Ana I. Robles; Terry Hyslop; Yujia Wen; Linda McCart; Azra Krek; Francesca Petralia; George Miles; Shyam M. Kavuri; Michael A. Gillette; D.R. Mani; Steven A. Carr; Bing Zhang; Matthew J. Ellis; Shankha Satpathy; Meenakshi Anurag
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab

HER2DX ERBB2 mRNA评分：用于接受化疗、曲妥珠单抗和帕妥珠单抗治疗的一线晚期HER2阳性乳腺癌

NPJ BREAST CANCER
IF7.6
2025-04-250
OA
Sanchez-Bayona, Rodrigo; Martinez-Saez, Olga; Romero-Romero, Denys; Segui, Elia; Carcelero, Esther; Tolosa, Pablo; Soberino, Jesus; Alva, Manuel; Pascual, Tomas; Lema, Laura; Garcia-Fructuoso, Isabel; Cobos-Fernandez, Maria Angeles; Rey, Maria; Manso, Luis; Aguirre, Angela; Madariaga, Ainhoa; Sirenko, Valeria; Gonzalez-Deza, Cristina; Blasco, Paula; Mayhua, Astrid; Castillo, Oleguer; Galvan, Patricia; Sanfeliu, Esther; Villacampa, Guillermo; Buckingham, Wesley; Marin-Aguilera, Mercedes; Pare, Laia; Villagrasa, Patricia; Perou, Charles M.; Maues, Julia; Braso-Maristany, Fara; Ciruelos, Eva
Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy
COMMUNICATIONS MEDICINE
IF6.3
2025-01-080
OA
Yazdani, Akram; Lenz, Heinz-Josef; Pillonetto, Gianluigi; Mendez-Giraldez, Raul; Yazdani, Azam; Sanoff, Hanna; Hadi, Reza; Samiei, Esmat; Venook, Alan P.; Ratain, Mark J.; Rashid, Naim; Vincent, Benjamin G.; Qu, Xueping; Wen, Yujia; Kosorok, Michael; Symmans, William F.; Shen, John Paul Y. C.; Lee, Michael S.; Kopetz, Scott; Nixon, Andrew B.; Bertagnolli, Monica M.; Perou, Charles M.; Innocenti, Federico
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer

MEK抑制剂曲美替尼单独或与AKT抑制剂GSK2141795/乌普罗替尼联合治疗转移性三阴性乳腺癌患者的II期研究

BREAST CANCER RESEARCH AND TREATMENT
IF3
2024-12-071
PRE
Prasath, Vishnu; Boutrid, Hinda; Wesolowski, Robert; Abdel-Rasoul, Mahmoud; Timmers, Cynthia; Lustberg, Maryam; Layman, Rachel M.; Macrae, Erin; Mrozek, Ewa; Shapiro, Charles; Glover, Kristyn; Vater, Mark; Budd, G. Thomas; Harris, Lyndsay; Isaacs, Claudine; Dees, Claire; Perou, Charles M.; Johnson, Gary L.; Poklepovic, Andrew; Chen, Helen; Villalona-Calero, Miguel; Carson, William; Stover, Daniel G.; Ramaswamy, Bhuvaneswari
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)

HER2阳性早期乳腺癌（EBC）患者新辅助治疗期间残留病灶（RD）生物学及基因表达变化的预后价值

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Fernandez-Martinez, A.; Tanioka, M.; Ahn, S. G.; Zagami, P.; Pascual, T.; Rediti, M.; Tang, G.; Hoadley, K. A.; Venet, D.; Rashid, N. U.; Spears, P. A.; Llombart-Cussa, A.; Di Cosimo, S.; de Azambuja, E.; Choudhury, A.; Rastogi, P.; Islam, M. N.; Swain, S. M.; Cortes, J.; Sotiriou, C.; Prat, A.; Perou, C. M.; Carey, L. A.
Generative adversarial networks accurately reconstruct pan-cancer histology from pathologic, genomic, and radiographic latent features

生成对抗网络从病理，基因组和影像学潜在特征准确地重建了泛癌症组织学

SCIENCE ADVANCES
IF12.5
2024-11-150
OAAI
Howard, Frederick M.; Hieromnimon, Hanna M.; Ramesh, Siddhi; Dolezal, James; Kochanny, Sara; Zhang, Qianchen; Feiger, Brad; Peterson, Joseph; Fan, Cheng; Perou, Charles M.; Vickery, Jasmine; Sullivan, Megan; Cole, Kimberly; Khramtsova, Galina; Pearson, Alexander T.
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
SCIENTIFIC REPORTS
IF3.9
2024-07-112
OAAI
Lorman-Carbo, Natalia; Martinez-Saez, Olga; Fernandez-Martinez, Aranzazu; Galvan, Patricia; Chic, Nuria; Garcia-Fructuoso, Isabel; Rodriguez, Adela; Gomez-Bravo, Raquel; Schettini, Francesco; Blasco, Paula; Castillo, Oleguer; Gonzalez-Farre, Blanca; Adamo, Barbara; Vidal, Maria; Munoz, Montserrat; Perou, Charles M.; Malumbres, Marcos; Gavila, Joaquin; Pascual, Tomas; Prat, Aleix; Braso-Maristany, Fara

研究方向

暂未获取到该数据
J
Joel S. Parker
H 指数:135论文数:1,028被引数:12.3万
A
Aleix Prat
H 指数:92论文数:1,351被引数:3.6万
K
Katherine A. Hoadley
H 指数:136论文数:792被引数:16.5万
L
Lisa A. Carey
H 指数:104论文数:988被引数:5.3万
M
Melissa A. Troester
H 指数:60论文数:1,041被引数:1.7万
X
Xiaping He
H 指数:40论文数:179被引数:1.9万
C
Cheng Fan
H 指数:40论文数:90被引数:1.0万
F
Fara Brasó‐Maristany
H 指数:28论文数:304被引数:3,706
M
Matthew J. Ellis
H 指数:108论文数:1,048被引数:6.5万
L
Laia Paré
H 指数:43论文数:431被引数:7,230